Immunic links vidofludimus calcium to cognition gains and neuron protection
Immunic, Inc. (NASDAQ:IMUX) reported post-hoc CALLIPER analysis linking vidofludimus calcium with reduced Epstein-Barr virus (EBV)-specific T-cell receptors and improved cognitive performance. The analysis also examined a bidirectional disability endpoint for future progressive multiple sclerosis trials.
Separate preclinical findings indicated that vidofludimus calcium promoted human neuron survival through Nurr1, reduced microglia-driven neuron loss in laboratory testing and improved disease markers in an MS model. The findings could help inform trial endpoints, although the cognition analysis was post-hoc and the neuron data were preclinical.
Immunic shares were recently at $8.19, up 8.33% on the day. Investors may next focus on how the company translates these findings into clinical trial design and whether later-stage data support the observed effects.
Key points
- CALLIPER post-hoc analysis linked vidofludimus calcium to lower EBV-specific T-cell receptor levels.
- The analysis associated the reduction with improved cognition.
- Preclinical data showed neuron survival through Nurr1 activation.
- Vidofludimus calcium reduced microglia-driven neuron loss in vitro.
- Immunic shares were at $8.19, up 8.33% on the day.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did Immunic report about vidofludimus calcium and cognition?
A post-hoc CALLIPER analysis linked reduced EBV-specific T-cell receptors after treatment with improved cognitive performance.
How could Immunic’s preclinical data affect future MS trials?
The findings may help inform trial endpoints after showing neuron survival via Nurr1, reduced microglia-driven neuron loss and improved MS model markers.